Experience the grandeur of GlaxoSmithKline’s headquarters in London, captured in a stunning view on January 17, 2022. Witness the epitome of innovation and excellence in the pharmaceutical industry.
In a groundbreaking move, the Food and Drug Administration has broadened its approval of GSK’s respiratory syncytial virus vaccine, Arexvy, to include adults aged 50 to 59. This milestone offers protection to a demographic at heightened risk of severe illness from this potentially fatal virus.
Previously sanctioned for individuals aged 60 and above, this vaccine now extends its shield to a younger population vulnerable to the ravages of RSV. The CDC reports a significant number of hospitalizations and fatalities among seniors due to RSV annually, emphasizing the critical need for preventive measures.
Adults aged 50 and older, particularly those with underlying health conditions like asthma, diabetes, and heart failure, face a considerable threat from RSV. With approximately 13 million Americans in this age group at risk, GSK’s initiative marks a pivotal advancement in safeguarding public health.
Join us in celebrating this milestone in medical history as GSK continues to lead the charge in protecting lives and promoting well-being.
2024-06-07 17:21:42
Source from www.cnbc.com
